Triple-Drug cocktail aims to tackle esophageal cancer that resists standard therapy
NCT ID NCT07686926
First seen Jul 07, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This phase II trial tests a combination of three drugs—Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib—in people with advanced esophageal squamous cell carcinoma whose cancer has progressed after first-line therapy. The study aims to see if this triple therapy can shrink tumors and improve survival. Participants receive the drugs intravenously and orally over several cycles, with the main goal of measuring how many patients respond to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Becotatug Vedotin, Tislelizumab, and Lenvatinib
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with advanced esophageal cancer who have run out of effective therapies.
- What could go wrong
- This is a small, early-phase study with only 36 participants, so results may not apply broadly. The combination of three drugs may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads
- Could a genetic marker guide future cancer therapies in taiwan?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New drug cocktail aims to shrink Hard-to-Treat esophageal tumors
- Smart T-Cell engager aims to outsmart tumors in first human test